Evaxion's Clinical Advances in Cancer Vaccination
Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company focused on pioneering AI-Immunology™ powered vaccines, is set to share significant two-year clinical efficacy findings from its phase 2 trial involving the personalized cancer vaccine EVX-01. This essential data will be unveiled at the esteemed European Society for Medical Oncology (ESMO) Congress happening in Berlin.
The Power of AI in Cancer Treatment
Developed utilizing Evaxion’s innovative AI-Immunology™ platform, EVX-01 represents a next-generation approach to cancer treatment, currently under evaluation for advanced melanoma cases. During earlier trials, the interim findings showcased exceptional outcomes, including a notable 69% overall response rate and a majority of patients achieving reductions in tumor sizes.
“We are excited to present the two-year data from our EVX-01 phase 2 trial at such a significant oncology conference. This venue allows us to reach a broad audience and connect with potential collaborators,” stated Birgitte Rønø, the CSO and interim CEO of Evaxion, highlighting the importance of their contributions to cancer research.
Details of the Presentation at ESMO
The research focuses on EVX-01 in tandem with MSD’s anti-PD-1 treatment, KEYTRUDA® (pembrolizumab), targeting patients battling advanced melanoma. Each vaccine is crafted individually for each participant based on their unique tumor profile, allowing for a tailored immunological response to cancer.
Presentation Highlights
During the congress, the abstract titled “EVX-01, a personalized cancer vaccine, induces potent T-cell responses and durable disease control in advanced melanoma: 2-year follow-up” will be highlighted. The presentation is scheduled for October 17, at the Nuremberg Auditorium, featuring Dr. Muhammad Adnan Khattak from One Clinical Research. Participants can anticipate discussing the remarkable advancements in personalized treatment.
About EVX-01
EVX-01 stands as Evaxion's flagship clinical asset, designed to serve as a first-line treatment option across multiple advanced solid cancers. Its innovative formulation employs a patient’s specific immune characteristics to create an effective therapeutic response against tumors. In past trials, EVX-01 has shown promising clinical responses, with 67% of evaluated metastatic melanoma patients exhibiting objective clinical responses.
The predictive capabilities of the AI-Immunology™ platform enhance the understanding of individual immune responses, establishing a strong correlation between clinical results and AI-derived predictions.
About Evaxion
Evaxion is at the forefront of applying artificial intelligence to unlock new immunotherapies for various diseases, including different types of cancer. Their goal is to transform healthcare through personalized and targeted treatment options. The company is dedicated to advancing medical science by using AI to address unmet medical needs and improve patient outcomes.
Contact Information
For inquiries, please reach out to:
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
Frequently Asked Questions
What is EVX-01?
EVX-01 is a personalized cancer vaccine developed by Evaxion, utilizing AI to tailor treatments for advanced melanoma patients.
When will the ESMO Congress take place?
The ESMO Congress will be held from October 17 to October 21, 2025.
What are the key findings from the two-year trial data?
The trial results revealed a 69% overall response rate and significant tumors reductions among patients.
Who is presenting at the ESMO Congress?
Dr. Muhammad Adnan Khattak will present the findings at the congress.
How is Evaxion utilizing AI technology?
Evaxion uses its AI-Immunology™ platform to create personalized immunotherapies that target specific immune responses in patients.
